Holen Sie sich die Stockscreener-App
9.63
2.03%
-0.20
Handel nachbörslich:
9.63
Schlusskurs vom Vortag:
$9.83
Offen:
$9.97
24-Stunden-Volumen:
5,095
Relative Volume:
0.22
Marktkapitalisierung:
$48.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.86M
KGV:
-5.7321
EPS:
-1.68
Netto-Cashflow:
$-125.29M
1W Leistung:
-2.73%
1M Leistung:
+2.67%
6M Leistung:
-45.57%
1J Leistung:
-41.20%
1-Tages-Spanne:
$9.6247
$9.97
1-Wochen-Bereich:
$9.55
$10.41
52-Wochen-Spanne:
$7.96
$24.15
Allovir Inc Stock (ALVR) Company Profile
Firmenname
Allovir Inc
Sektor
Branche
Telefon
(617) 433-2605
Adresse
1100 WINTER STREET, WALTHAM
Vergleichen Sie ALVR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
9.63 | 48.55M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-26 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-22 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2023-12-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-18 | Eingeleitet | BofA Securities | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-08-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Allovir Inc Aktie (ALVR) Neueste Nachrichten
Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - ACCESS Newswire
ALVR SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
UPCOMING ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of EMKR, CCRN, WMPN, ALVR to Act Now - GlobeNewswire Inc.
(ALVR) Technical Pivots with Risk Controls - Stock Traders Daily
AlloVir (NASDAQ:ALVR) Stock Price Up 0.5%Should You Buy? - MarketBeat
IMMINENT ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
AlloVir (NASDAQ:ALVR) Stock Price Up 0.5% – Should You Buy? - Defense World
$TOCKHOLDER ALERT: The M&A Class Action Firm Urges Shareholders of OMIC, BERY, WMPN, ALVR to Act Now - The Malaysian Reserve
Allovir director Vikas Sinha sells $1,225 in stock - MSN
Allovir's chief accounting officer sells $342 in common stock - MSN
Allovir's general counsel sells $494 in stock - MSN
Allovir's general counsel sells $494 in stock By Investing.com - Investing.com South Africa
Allovir's chief accounting officer sells $342 in common stock By Investing.com - Investing.com South Africa
Allovir director Vikas Sinha sells $1,225 in stock By Investing.com - Investing.com Australia
Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline - GuruFocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerCYTH, ALVR, WMPN, OMC - Morningstar
ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Inve - GuruFocus.com
AlloVir (NASDAQ:ALVR) Trading 8.2% HigherHere's What Happened - MarketBeat
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - Marketscreener.com
AlloVir (NASDAQ:ALVR) Hits New 1-Year LowWhat's Next? - MarketBeat
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc - Marketscreener.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - Marketscreener.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. LawsuitALVR - Marketscreener.com
Jane Street Group LLC Sells 89,680 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
AlloVir executes reverse stock split By Investing.com - Investing.com Australia
AlloVir executes reverse stock split - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Allovir's general counsel Edward Miller sells $180 in stock - Investing.com India
Allovir stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com Canada
Allovir’s Vikas Sinha sells shares worth $430 By Investing.com - Investing.com Nigeria
Allovir's Vikas Sinha sells shares worth $430 By Investing.com - Investing.com Australia
Allovir’s general counsel Edward Miller sells $180 in stock By Investing.com - Investing.com Nigeria
Allovir’s chief accounting officer sells $146 in common stock By Investing.com - Investing.com Nigeria
Allovir's chief accounting officer sells $146 in common stock By Investing.com - Investing.com Australia
Allovir's general counsel Edward Miller sells $180 in stock By Investing.com - Investing.com Australia
Allovir's chief accounting officer sells $146 in common stock - Investing.com India
Finanzdaten der Allovir Inc-Aktie (ALVR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):